
Teniposide Suppliers & Bulk Manufacturers
Available Forms: Injection (IV)
Available Strengths: 50 mg/5 mL (10 mg/mL vial)
Reference Brands: Vumon® (EU & US)
Category: Oncology Cancer Care
Teniposide is available in Injection (IV) and strengths such as 50 mg/5 mL (10 mg/mL vial). Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Teniposide is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
Technical Specifications & Supply Details | |
---|---|
Lead Time | 7 to 60 days (depending on batch size & schedule) |
MOQ | As per manufacturer’s batch size |
COA | Available with every batch |
Regulatory Dossier / DMF | Available upon request |
Export Documentation | FSC, COA, Manufacturing License, Product Permission |
Standards | IP, BP, USP |
Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Teniposide can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Teniposide Injection is a potent chemotherapeutic agent used in the treatment of acute lymphoblastic leukemia (ALL), especially in pediatric patients with relapsed or refractory disease. Classified as a topoisomerase II inhibitor, Teniposide disrupts DNA replication and cell division, making it effective in oncology protocols. It is commercially available in the US and EU under the brand name Vumon®, typically in 50 mg/5 mL (10 mg/mL) injectable vials. Teniposide is manufactured under strict GMP standards, making it ideal for B2B pharmaceutical distributors, hospital tenders, and global supply chains seeking reliable oncology solutions in regulated markets.
Frequently Asked Questions
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View DetailsDurvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View DetailsSunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers